IL10 and neoplasm: In summary, the intratumoral delivery methods and sustainability of therapeutic IL-10 (or its biologically active isoforms), specifically designed to interact with critical targets within the TME, are critical considerations to effectively mediate multimodal antitumor activity within tumor tissues while reducing systemic adverse effects and minimizing inhibitory impacts on non-target cell types.